期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Research progress in the influence of EGFR genovariation on the clinical efficacy of gefitinib treatment of non-small cell lung cancer 被引量：1

下载PDF
导出
摘要 As an epidermal growth factor receptor(EGFR)tyrosine kinase lung cancer-targeted drug,gefitinib has been widely applied in the treatment of non-small cell lung cancer(NSCLC).The present clinical application has shown that EGFR genovariation might cause the abnormal expression of lung cancer cells,it makes its sensibility to gefitinib decrease,and the clinical efficacy will be decreasing accordingly.Based on these problems,the effects of EGFR genovariation on the clinical efficacy of gefitinib treatment of NSCLC was further analyzed,and the successive development was summarized.
作者 Yang Wang Jiang Zhu
机构地区 West China School of Medicine Department of Oncology Department of Thoracic Oncology
出处 《Journal of Hainan Medical University》 2018年第2期156-160,共5页 海南医学院学报（英文版）
关键词 EPIDERMAL growth factor RECEPTOR Genovariation GEFITINIB NON-SMALL cell LUNG cancer
分类号 R73 [医药卫生—肿瘤]
  • 相关文献

参考文献9

二级参考文献94

  • 1Zhou C, Wu Y L,Chen G’Feng J,Liu X Q, Wang C,etal. Erlotinib versus chemotherapy as first-line treatmentfor patients with advanced EGFR mutation-positivenon-small-cell lung cancer ( OPTIMAL, CTONG-0802) : a multicentre,open-label, randomised, phase 3study[J]. Lancet Oncol,2011,12:735-742.
  • 2Tamura K, Okamoto 1? Kashii T, Negoro S, HirashimaT,Kudoh S,et al. Multicentre prospective phase H trialof gefitinib for advanced non-small cell lung cancer withepidermal growth factor receptor mutations : results ofthe West Japan Thoracic Oncology Group trial (WJ-TOG0403) [J]. Br J Cancer,2008,98 : 907-914.
  • 3Nguyen K S, Kobayashi S, Costa D B. Acquired resist-ance to epidermal growth factor receptor tyrosine kinaseinhibitors in non-small-cell lung cancers dependent onthe epidermal growth factor receptor pathway[J]. ClinLung Cancer,2009 ,10 :281-289.
  • 4Casa A J ,Dearth R K,Litzenburger B C,Lee A V,CuiX. The type 工 insulin-like growth factor receptor path-way . a key player in cancer therapeutic resistance [J],Front Biosci,2008,13 :3273-3287.
  • 5Adams T E,Epa V C,Garrett T P,Ward C W. Struc-ture and function of the type 1 insulin-like growth fac-tor receptor[J], Cell Mol Life Sci,2000,57 :1050-1093.
  • 6Camirand A, Zakikhani M,Young F,Poliak M. Inhibi-tion of insulin-like growth factor-1 receptor signalingenhances growth-inhibitory and proapoptotic effects ofgefitinib (Iressa) in human breast cancer cells [ J].Breast Cancer Res,2005,7 :R570-R579.
  • 7Guix M,Faber A C, Wang S E,Olivares M G,Song Y,Qu S,et al. Acquired resistance to EGFR tyrosine ki-nase inhibitors in cancer cells is mediated by loss ofIGF-binding proteins[J]. J Clin Invest,2008,118 : 2609-2619.
  • 8Jones H E,Goddard L, Gee J M, Hiscox S, Rubini M,Barrow D,et al. Insulin-like growth factor- I receptorsignaling and acquired resistance to gefitinib (ZD1839 ;Iressa) in human breast and prostate cancer cells[J],Endocrine Related Cancer,2004?11 : 793-814.
  • 9Jackman D,Pao W,Riely G J,Engelman J A,Kris M G,Janne P A, et al. Clinical definition of acquired resist-ance to epidermal growth factor receptor tyrosine kinaseinhibitors in non-small-cell lung cancer[J]. J Clin On-col, 2010,28 : 357-360.
  • 10Masago K, Fujita S, Togashi Y, Kim Y H, Hatachi Y,Fukuhara A,et al. Clinical significance of epidermalgrowth factor receptor mutations and insulin-likegrowth factor 1 and its binding protein 3 in advancednon-squamous non-small cell lung cancer [J]. OncolRep,2011,26;795-803.

共引文献64

同被引文献11

引证文献1

Journal of Hainan Medical University
2018年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部